The Alzheimer’s Association International Conference (AAIC 2021) is underway virtually as well as in-person in Denver, Colorado. The hybrid conference started Monday and continues through Friday July 30. Sessions at the meeting focus on clinical treatment and research of Alzheimer disease including biomarkers, disease prevention and treatment, social determinants, and genetics of the disease. This […]
Chengran Yang, a PhD candidate in the lab of Carlos Cruchaga, is the first author of a manuscript just published in the prestigious journal Nature Neuroscience. He used multi-tissue proteomics to identify hundreds of proteins that are genetically regulated. By using statistical methods, such as Mendelian randomization, he was able to implicate several of these […]
The Alzheimer’s Disease/Parkinson’s disease (AD/PD) annual conference began yesterday and will continue through Sunday, March 14. The virtual conference provides 6 full days of scientific presentations and symposia including a mix of pre-recorded oral presentations and live discussions with presenters. The NGI is represented by 10 of our own researchers who are presenting their recent […]
The NGI will be hosting a Workshop on the “Application of Machine Learning Tools to Omics in Neuroscience” on February 18, 2021. This full-day, virtual event will feature basic introductory sessions on Machine Learning, plenary lectures by invited speakers, oral presentations of submitted abstracts, and a round table discussion. Everyone is invited to register by […]
Drs. Harari, Benitez, Karch and Cruchaga leveraged biospecimens obtained from large and well-characterized human cohorts to identify a novel protective gene for Alzheimer disease, MS4A4A, that is also the major regulator of TREM2. This study provides a strong evidence of a biological link between TREM2 and MS4A4A in microglia in the context of AD. However, […]
Drs. Cruchaga and Karch are some of the Washington University investigators that received funding from Centene to perform molecular phenotyping of Alzheimer’s cases to identify novel molecular biomarkers and the identification of novel therapeutically targets. Specifically we plan to develop a personalized medicine approach to understand the effects of Alzheimer’s disease risk genes by combining […]
Dr. Cruchaga discuss about the use of polygenic risk scores to predict individual level risk for Alzheimer and provide this data “direct-to-consumer”.
In collaboration with Alzforum Dr. Cruchaga analyses the impact of direct-to-consumer genetic testing.
Geneticists are inventing new ways to hunt AD variants that went undetected in GWAS and might shed light on AD pathogenesis. Many labs are searching for polymorphisms tied to specific quantitative traits. As Yuetiva Deming from Carlos Cruchaga’s group at Washington University, St. Louis, pointed out, GWAS identify risk variants but say nothing about how that risk manifests